Timeline

Voting rights breakdown

Declared beneficial owners · 23

A single, collectively filed disclosure: the voting-rights rate applies to the whole group, not to each person.

• Aravis Venture I LP3%
• Astellas Venture Capital, LLC3%
• Auriga Ventures III3%
• Baltisches Haus Limited3%
• BioMedInvest II LP3%
• A/S Dansk Erhvervsinvestering3%
• Entrepreneurs Fund General Partners Limited3%
• Evolva Holding SA3%
• Mona Lisa Capital SA3%
• Novartis Bioventures Ltd3%
• Renaisance PME fondation suisse d investissement / Mona Lisa3%
• Sunstone Life Science Ventures Fund I K/S3%
• Symbion Capital I A/S3%
• Wellington Partners Ventures III Life Science Fund L.P3%
• Wellington Partners Ventures III Life Science Network Fund L3%
• Neil Goldsmith3%
• Alexandra SantAna Sørensen3%
• Pascal Longchamp3%
• Jakob Dynnes Hansen3%
• Jutta Heim3%
• PM Murali3%
• Vaekstfonden3%
• Abunda SR, LLC3%

Notice details

Beneficial owner

Aravis Venture I LP

On 18 August 2011, Evolva announced that one of the investors in the Sale Pool had given notice of its intention to end its participation in the coordinated sale process. This has led to the discontinuation of the coordinated sales process as of Friday 19 August 2011, with the remaining shares that were included in the process being returned to the parties on or after 30 August, 2011. Thereafter each party is free to trade its shares at its own discretion - triggering the present disclosure.